Viatris Inc Stock: price and insider trades · United States

This page follows insider dealings at Viatris Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Pittsburgh, United States. The group dates from 2020. From 18 October 2025 to 18 October 2026, the disclosure feed for Viatris Inc logged 34 filings by 18 insiders.

Open-market activity splits into 1 purchase totalling €2,559 and 2 sales totalling €245k; 1 insider sit on the buying side and 1 insider on the selling side. The amount is not disclosed for 1 filing. Unlike grants, an open-market purchase is paid for by the insider, at the market price. At €245k, the sale published on 24 March 2026 by Campbell Paul is the largest of the period. Those buying include 1 senior executive.

The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 10 March 2026, 222 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

With 34 filings in twelve months, the company is more active than the median of 19 filings across the 5,816 companies we follow on the same exchange. Since 2021, the database holds 7 purchases and 17 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 14.30 bn USD and net income at -3.51 bn USD, and the dividend at 0.48 USD per share.

In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.